EP1031034A4 - Verfahren zum diagnostizieren der alzheimerschen krankheit - Google Patents

Verfahren zum diagnostizieren der alzheimerschen krankheit

Info

Publication number
EP1031034A4
EP1031034A4 EP98957464A EP98957464A EP1031034A4 EP 1031034 A4 EP1031034 A4 EP 1031034A4 EP 98957464 A EP98957464 A EP 98957464A EP 98957464 A EP98957464 A EP 98957464A EP 1031034 A4 EP1031034 A4 EP 1031034A4
Authority
EP
European Patent Office
Prior art keywords
disease
diagnosing alzheimer
alzheimer
diagnosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98957464A
Other languages
English (en)
French (fr)
Other versions
EP1031034A1 (de
Inventor
Jeffrey K Aronson
Silva Asita H De
David G Grahame-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1031034A1 publication Critical patent/EP1031034A1/de
Publication of EP1031034A4 publication Critical patent/EP1031034A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP98957464A 1997-11-10 1998-11-02 Verfahren zum diagnostizieren der alzheimerschen krankheit Withdrawn EP1031034A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6477997P 1997-11-10 1997-11-10
US64779P 1997-11-10
PCT/US1998/023198 WO1999024830A1 (en) 1997-11-10 1998-11-02 Method for diagnosing alzheimer's disease

Publications (2)

Publication Number Publication Date
EP1031034A1 EP1031034A1 (de) 2000-08-30
EP1031034A4 true EP1031034A4 (de) 2004-11-17

Family

ID=22058224

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98957464A Withdrawn EP1031034A4 (de) 1997-11-10 1998-11-02 Verfahren zum diagnostizieren der alzheimerschen krankheit

Country Status (5)

Country Link
EP (1) EP1031034A4 (de)
JP (1) JP2001523002A (de)
AU (1) AU750582B2 (de)
CA (1) CA2308371A1 (de)
WO (1) WO1999024830A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077686A2 (en) * 2000-04-05 2001-10-18 Neurologic, Inc. Cellular calcium responce for diagnosis of alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580748A (en) * 1993-05-03 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tests for alzheimers disease
US5652111A (en) * 1992-07-30 1997-07-29 American Cyanamid Company Binding assay utilizing a nucleic acid encoding apamin binding protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
US5778893A (en) * 1991-04-01 1998-07-14 President And Fellows Of Harvard College Method of diagnosing and monitoring a treatment for Alzheimer's disease
DE4430638A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652111A (en) * 1992-07-30 1997-07-29 American Cyanamid Company Binding assay utilizing a nucleic acid encoding apamin binding protein
US5580748A (en) * 1993-05-03 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tests for alzheimers disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DE SILVA H A ET AL: "Abnormal function of potassium channels in platelets of patients with Alzheimer's disease.", LANCET. 14 NOV 1998, vol. 352, no. 9140, 14 November 1998 (1998-11-14), pages 1590 - 1593, XP004265818, ISSN: 0140-6736 *
DE SILVA H A ET AL: "Effects of high external concentrations of K+ on 86Rb+ efflux in human platelets: Evidence for Na+/K+/2Cl- co-transport", CLINICAL SCIENCE (LONDON), vol. 91, no. 6, 1996, pages 725 - 731, XP008033753, ISSN: 0143-5221 *
DE SILVA H A ET AL: "Pharmacological evidence of calcium-activated and voltage-gated potassium channels in human platelets", CLINICAL SCIENCE (LONDON), vol. 93, no. 3, 1997, pages 249 - 255, XP008033751, ISSN: 0143-5221 *
DE SILVA H A ET AL: "Stimulation of potassium (86Rubidium) efflux from human platelets by external potassium and its inhibition by bumetanide: Evidence for Na/K/Cl co-transport", BRITISH JOURNAL OF PHARMACOLOGY, vol. 117, no. PROC. SUPPL., 1996, & MEETING OF THE BRITISH PHARMACOLOGICAL SOCIETY; LONDON, ENGLAND, UK; DECEMBER 13-15, 1995, pages 115P, XP008033752, ISSN: 0007-1188 *
ETCHEBERRIGARAY RENE ET AL: "Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 90, no. 17, 1993, pages 8209 - 8213, XP002291606, ISSN: 0027-8424 *
See also references of WO9924830A1 *

Also Published As

Publication number Publication date
EP1031034A1 (de) 2000-08-30
AU750582B2 (en) 2002-07-25
AU1371699A (en) 1999-05-31
CA2308371A1 (en) 1999-05-20
WO1999024830A1 (en) 1999-05-20
JP2001523002A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
EP1043991A4 (de) Behandlung der alzheimer-erkrankung
EP0951293A4 (de) Verfahren zur behandlung von alzheimer krankheit
AU3891499A (en) Diagnostic tests for alzheimer's disease
AU7708498A (en) Nematode model for alzheimer's disease
HUP0103838A3 (en) Alzheimer's disease secretase
EP0773797A4 (de) Verfahren zur diagnose der alzheimer'schen erkrankung
AU2414092A (en) Diagnostic method for alzheimer's disease
AU5508798A (en) Diagnostic and therapeutic reagents for alzheimer's disease
IL132186A0 (en) Method for diagnosing psychiatric disorders
AU2610901A (en) Predictive diagnostic for alzheimer's disease
AP9701126A0 (en) Method for diagnosing schizophrenia
AU1403402A (en) Radiopharmaceuticals for diagnosing alzheimer's disease
IL135584A0 (en) Method for treating alzheimer's disease
IL119417A0 (en) Drug for Parkinson's disease
HUP0003684A3 (en) Diagnostic test for alzheimer's disease
IL140222A0 (en) A method and diagnostic kit for detecting alzheimer's disease
AUPN649395A0 (en) A method for diagnosing alzheimer's disease
AU8346498A (en) Method for diagnosing alzheimer disease
AU1405899A (en) Treatment for alzheimer's disease
AU9017098A (en) Method for diagnosing alzheimer's disease
ZA971716B (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimer's disease
AU5495398A (en) Idebenone containing combination agent for treating alzheimer's disease
HUP0003325A3 (en) Method for producing n-alkyl-n'-nitroguanidines
GB9706395D0 (en) Methods for clinical diagnosis
HK1029809A (en) Diagnostic test for alzheimer's disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/68 B

Ipc: 7G 01N 33/20 A

A4 Supplementary search report drawn up and despatched

Effective date: 20041001

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041218